The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScancell Holdings Share News (SCLP)

Share Price Information for Scancell Holdings (SCLP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.15
Bid: 8.80
Ask: 9.50
Change: 0.05 (0.55%)
Spread: 0.70 (7.955%)
Open: 9.10
High: 9.15
Low: 8.70
Prev. Close: 9.10
SCLP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sector movers: Pharmaceuticals under the weather as AstraZeneca takes a hit

Thu, 31st Jan 2013 15:04

The pharmaceuticals and biotechnology sector was at the bottom of the pile on Thursday after a disappointing set of full-year results from AstraZeneca weighed on share prices.The company, which manufactures drugs to treat range of cardiovascular conditions, reported a 15% fall in revenue at constant exchange rates (CER) from $33.59bn to $27.97bn due to a loss of exclusivity on several brands. Core earnings per share (EPS) dropped 9.0% from $7.28 to $6.41.Furthermore, the firm said it expects a "mid-to-high single digit percentage decline" in revenue at CER this year. Meanwhile, core EPS will decline "significantly more" than revenue due to higher operating costs.Analyst Savvas Neophytou from Panmure Gordon said that consensus estimates for 2013 would likely come down. He maintained a 'hold' rating for AstraZeneca.With the stock having had a good run recently, Neophytou said that shares are "up with events" for the moment, with the discount to the European pharmaceutical sector justified given "perceived increased forecast risk". AIM-listed medial company Scancell was in the red after reporting an operating loss of £0.99m in its first half, slightly worse than the year before.Veterinary pharmaceutical group Dechra was also lower after appointing a new Chief Financial Officer. Anne-Francoise Nesmes will join the company in April from GlaxoSmithKline where she has worked since 1997 in a number of finance roles including Senior Vice-President, Finance of Vaccines in Belgium. However, a strong rise from FTSE 250 specialist healthcare business BTG did limit losses in the sector, after the company said that full-year revenues would likely be at the 'top end' of guidance.BTG said the last three months have wielded positive results, particularly from acute care items. The board now anticipates revenues for the year to March 31st to reach the higher point of its estimate between £205m to £215m. Top performing sectors so far todayBeverages 14,079.42 +1.61%Construction & Materials 3,757.56 +1.45%Oil Equipment, Services & Distribution 25,125.83 +1.36%Forestry & Paper 8,073.13 +1.22%Mining 20,242.12 +0.95%Bottom performing sectors so far todayPharmaceuticals & Biotechnology 10,070.84 -1.13%Oil & Gas Producers 8,244.19 -1.11%Software & Computer Services 989.53 -1.06%Industrial Metals & Mining 2,974.72 -0.91%Chemicals 8,874.18 -0.86%BC
More News
22 Oct 2021 16:05

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
19 Oct 2021 20:41

IN BRIEF: Scancell bases new facility at Oxford Science Park

IN BRIEF: Scancell bases new facility at Oxford Science Park

Read more
5 Oct 2021 22:03

IN BRIEF: Scancell doses first subject in Covidity phase one trial

IN BRIEF: Scancell doses first subject in Covidity phase one trial

Read more
26 Aug 2021 12:53

TRADING UPDATES: Caerus, Bezant pick Cyprus asset; TomCo buys JV

TRADING UPDATES: Caerus, Bezant pick Cyprus asset; TomCo buys JV

Read more
26 Aug 2021 12:38

Scancell gets MHRA approval for Modi-1 clinical trial

(Sharecast News) - Immunotherapy developer Scancell announced on Thursday that the UK Medicines and Healthcare products Regulatory Authority (MHRA) has approved the clinical trial application to initiate the first-in-human phase 1 and 2 clinical study of 'Modi-1'.

Read more
17 Aug 2021 15:32

Scancell chooses needle-free tech for Covid vaccine candidates

(Sharecast News) - Cancer and infectious disease immunotherapy developer Scancell has selected the PharmaJet needle-free injection system to administer its two SARS-CoV-2 vaccine candidates for Covid-19, 'SCOV1' and 'SCOV2', in its 'COVIDITY' phase 1 clinical trial, it announced on Tuesday.

Read more
30 Jul 2021 14:24

DIRECTOR DEALINGS: Harbour Energy CEO for Europe buys 100,000 shares

DIRECTOR DEALINGS: Harbour Energy CEO for Europe buys 100,000 shares

Read more
29 Jul 2021 22:08

TRADING UPDATES: Salt Lake funding talks; Resolute cuts output outlook

TRADING UPDATES: Salt Lake funding talks; Resolute cuts output outlook

Read more
28 Jul 2021 22:00

IN BRIEF: Scancell turns once again to Durrant to lead company

IN BRIEF: Scancell turns once again to Durrant to lead company

Read more
22 Jun 2021 15:21

Scancell makes progress with 'Covidity' trial plans

(Sharecast News) - Immunotherapy developer Scancell updated the market on 'Covidity' clinical trial plans, and the publication of preclinical data on two vaccine candidates from the research programme.

Read more
22 Jun 2021 12:14

IN BRIEF: Scancell plans new Covid vaccine trial in South Africa, UK

IN BRIEF: Scancell plans new Covid vaccine trial in South Africa, UK

Read more
7 Jun 2021 13:58

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys more shares

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys more shares

Read more
7 Jun 2021 10:38

AIM WINNERS & LOSERS: NetScientific surges on Astra Covid test pact

AIM WINNERS & LOSERS: NetScientific surges on Astra Covid test pact

Read more
30 Apr 2021 14:30

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys 400,000 shares

IN BRIEF: Scancell Non-Exec Director Martin Diggle buys 400,000 shares

Read more
19 Feb 2021 20:13

IN BRIEF: Associate Of Scancell Director Sells GBP109,000 In Shares

IN BRIEF: Associate Of Scancell Director Sells GBP109,000 In Shares

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.